Clinical and pathological characteristics of congenital neuroblastoma in 15 Chinese infants: a retrospective analysis from a single-center Li’ou Zhu, Ying Wu, Wen Zhang, Qiong Feng, Dengyan Chen, Lili Liu Abstract AbstractObjectiveThis study aims to elucidate the clinicopathological characteristics, molecular profiles, and prognostic outcomes of congenital neuroblastoma in Chinese infants.MethodsA retrospective single-center analysis was conducted on 15 pathologically confirmed congenital neuroblastoma cases in China from 2017 to 2025. Clinical, imaging, pathological features and FISH for MYCN amplification and KMT2A rearrangement were evaluated.ResultsThe cohort included 15 patients with a male-to-female ratio of 8:7. Eight cases were detected prenatally and seven within 28 postnatal days. Most tumors (12/15) arose in the adrenal gland. Preoperative serum NSE elevation was more sensitive than VMA. All patients underwent complete resection; one received adjuvant chemotherapy and one relapsed. No MYCN amplification or KMT2A rearrangement was found.ConclusionIn this single-center Chinese cohort, congenital neuroblastoma showed favorable biological behavior. Complete resection achieved good outcomes. Combination of NSE and imaging examinations is promising for postoperative prognostic evaluation and recurrence surveillance in these pediatric patients.Keywords: adrenal tumor, clinicopathology, congenital neuroblastoma, infant, molecular markers, NSE Introduction Neuroblastoma represents the most prevalent extracranial solid malignant neoplasm in children younger than 2 years of age. A distinct subset, congenital neuroblastoma, is characterized by an unpredictable clinical trajectory, which may include spontaneous regression, differentiation into benign lesions, or malignant progression accompanied by metastasis (). These variable outcomes complicate clinical diagnosis, therapeutic decision-making, and prognostic evaluation. The present study conducted a retrospective analysis of clinical data from 15 patients, aiming to delineate their clinicopathological and molecular biological features. The findings are intended to inform and enhance diagnostic accuracy and treatment approaches. Materials and methods This study retrospectively collected cases of congenital neuroblastoma in pediatric patients who were admitted and treated at Wuhan Children’s Hospital between August 2017 and October 2025. The inclusion criteria were as follows: (1) diagnosis established within 28 days postpartum; (2) patients underwent surgical tumor resection, either complete or palliative; (3) postoperative pathological confirmation of neuroblastoma; (4) availability of comprehensive clinical, imaging, surgical, and pathological data; and (5) informed consent obtained from the patients’ guardians for follow-up and data analysis. All tumor specimens were fixed in 10% neutral buffered formalin, routinely dehydrated, and embedded in paraffin. Serial sections of 3.5 μm thickness were prepared and stained with hematoxylin and eosin (H&E) for routine histopathological evaluation. Immunohistochemical analyses were conducted to assess the expression of markers including phox2B, Synaptophysin (Syn), Neurofilament (NF), Neuron-Specific Enolase (NSE), and Chromogranin A (CgA). In selected cases, fluorescence in situ hybridization (FISH) was performed to evaluate the status of MYCN and/or KMT2A (11q23) genes. All pathological slides were independently reviewed and diagnoses confirmed by two senior attending pathologists. Results Clinical data and laboratory findings The cohort comprised 15 pediatric patients, with a male-to-female ratio of 8:7. Prenatal ultrasonography identified an abdominal mass in eight cases between 32 and 39 weeks of gestation (mean gestational age: 36 weeks). Seven cases were diagnosed within 28 days after birth, with two presenting due to jaundice and five due to symptoms such as persistent crying prompting imaging studies. Tumor localization was predominantly in the adrenal glands in 12 cases (10 left-sided, 2 right-sided), while three cases involved the mediastinum, neck, and retroperitoneum, respectively, with clear demarcation from the adrenal glands and kidneys (). All 15 tumors showed imaging features consistent with neuroblastoma, including 11 solid lesions and 4 cystic lesions. In Case 3, prenatal MRI using T2-weighted imaging (T2WI) at 33 weeks gestation revealed a round, heterogeneous mass with fluid–fluid levels located in the left adrenal gland (,). Following delivery of the infant, CT scans of the same lesion displayed a mainly hypodense mass with mixed density, containing several patchy areas of increased density (,). Laboratory analyses showed that preoperative serum neuron-specific enolase (NSE) testing was performed in 12 of the 15 patients (80%), including 11 cases with elevated NSE levels and 1 with normal levels (). Postoperative NSE data were collected from 10 of these 12 patients. All exhibited varying degrees of NSE reduction, and five patients’ levels returned to the normal range. All children underwent complete surgical resection of the tumors. Postoperative follow-up ranging from 47 to 71 months was performed in 12 patients with postoperative NSE follow-up data. Among them, NSE levels returned to the normal reference range in 7 patients and remained persistently elevated in five. The five patients with elevated postoperative NSE levels were divided into two groups. Three presented transient elevation, with levels normalizing within 3 months. Cases 8 and 9 showed recurrent fluctuations in NSE levels on serial follow-up examinations. Although their NSE levels remained high for a long time, no tumor recurrence was observed throughout follow-up, and their levels gradually approached the normal range at 47 and 49 months postoperatively, respectively. Of the seven patients with normalized postoperative NSE levels, one developed tumor recurrence, with the primary tumor located in the left posterior mediastinum. Quantitative vanillylmandelic acid (VMA) testing was completed preoperatively in 13 of the 15 patients, with elevated results detected in two patients. Pathological examination Gross pathology Gross examination of the 15 tumors revealed that 11 were solid and 4 were cystic. Tumor diameters ranged from 2.1 cm to 7.5 cm, with a mean diameter of 4.4 cm. The cut surfaces of solid tumors were gray-red, soft in consistency, and exhibited the characteristic fish-flesh appearance (). In cystic tumors, the cystic cavities contained turbid, dark red fluid; the cyst walls were smooth and measured approximately 0.1 cm to 0.3 cm in thickness (). Histological analysis In a cohort of 15 pediatric cases, histopathological evaluation identified 14 instances as poorly differentiated neuroblastoma, with one case classified as a composite neuroblastic tumor. Within this group, four cases represented distinct subtypes, specifically cystic neuroblastoma. Microscopic examination of the poorly differentiated solid neuroblastomas revealed tumor cells organized into nests or nodules at low magnification, separated by delicate fibrovascular stroma (). A neuropil background was evident within these nodules (). The tumor cells displayed characteristic small blue round cell morphology, featuring a high nucleus-to-cytoplasm ratio and frequent mitotic (). Cystic neuroblastoma predominantly manifested as cystic structures with relatively thick fibrous cyst walls (). Small blue round tumor cells were arranged in nests or nodules along the inner cyst wall (, red arrow) and within the cyst wall itself (, blue arrow). High magnification reveals nest-like clusters of these small blue round tumor cells within the cyst wall (,). In the sole case of composite neuroblastoma, multiple nodules were observed microscopically. As illustrated in , four nodules are present within the examined section, each containing diverse neuroblastoma components (–). Certain regions exhibited anaplastic features (). The inter-nodular area (, marked area 5/) consisted of fibrous stroma, with an absence of Schwann cell stroma. Assessment of proliferative activity indicated that, among the 15 cases, 10 exhibited a low mitosis-karyorrhexis index (MKI), 4 demonstrated a medium MKI, and 1 presented with a high MKI. Immunohistochemical analysis Immunohistochemical evaluation of tumor tissues from all 15 pediatric patients confirmed expression of neuroblastoma-specific markers (–, ). Phox2B demonstrated diffuse and strong positivity across all cases. CgA and Syn were diffusely positive in 13 cases, while the remaining two cases showed focal positivity. Additional markers, including Ki67, NSE, S-100 and NF, were variably expressed (). Molecular genetic analysis Among the 15 children in this group, 11 underwent MYCN gene amplification testing, of which 1 presented MYCN amplification ‘heterogeneous’, 8 showed MYCN gain, and 2 had normal NMYC status. As illustrated in , case 1 shows MYCN amplification ‘heterogeneous’, with amplification present in less than 10% of the tumor area and non-amplified cells detected in the remaining regions. This patient subsequently underwent whole-genome microarray analysis specific to pediatric neuroblastoma, which identified 20 acquired copy number variation (CNV) abnormalities, six of which were directly associated with neuroblastoma. Notably, no MYCN gene amplification was detected, nor was there any loss of heterozygosity (LOH) in the 1p or 11q chromosomal regions. Conversely, a gain was observed in the 17q11.2–q25.3 region. Chromosomal ploidy was near triploid, and the DNA copy number profile revealed only numerical chromosome aberrations (NCA), characterized by whole chromosome number changes. Among the 11 patients evaluated for MYCN amplification, 4 also underwent testing for KMT2A (11q23) gene deletion, with all results returning negative, as depicted in . Treatment Among the 15 patients, only one, whose primary tumor was located in the left adrenal gland with concurrent hepatic metastasis, underwent postoperative chemotherapy in accordance with the high-risk protocol specified in the “Expert Consensus on Diagnosis and Treatment of Pediatric Neuroblastoma (2015)” (). The remaining 14 patients did not receive any radiotherapy or chemotherapy either before or after surgical intervention. Based on the International Neuroblastoma Staging System (INSS) (), the distribution of disease stages was as follows: Stage I in 12 patients, Stage II in 2 patients, and Stage IV in 1 patient. Follow-up Follow-up assessments were conducted until October 30th, 2025. Two patients were lost to follow-up, while complete follow-up data were available for 13 patients, with durations ranging from 1 to 76 months and a median follow-up period of 10 months. The follow-up outcomes indicated that 12 children remained tumor-free survivors. However, one patient with a primary mediastinal tumor demonstrated a mediastinal shadow on computed tomography 6 months postoperatively, suggestive of tumor recurrence. Discussion Neuroblastoma is a tumor distinguished by heterogeneous levels of neuroblast differentiation and diverse stages of Schwann cell stroma maturation. It arises from neuroectodermal cells of the neural crest and represents the most prevalent extracranial solid malignant neoplasm in pediatric populations (). The term neonatal neuroblastoma specifically denotes cases diagnosed either prenatally or within the first 28 days postpartum. Data from the Children’s Oncology Group (COG) Statistics and Data Center indicate that neonatal neuroblastoma constitutes approximately 5% of all neuroblastoma incidences (). Our study included 15 pediatric patients diagnosed with congenital neuroblastoma. Benefiting from the advent and widespread application of prenatal diagnostic methodologies (, ), 8 of the cases were diagnosed via ultrasonography between 32 and 39 weeks of gestation. Consistent with Kostyrka B’s study (), all lesions in these 8 cases were located in the adrenal glands. This percentage is considerably higher than that seen in conventional neuroblastoma, the incidence of which is approximately 50%. In addition to the eight cases detected prenatally mentioned above, our cohort included seven neonatal cases (within 28 days after birth). Among these patients, four lesions originated from the adrenal glands, and the remaining three arose from other sites, including the neck, retroperitoneum and posterior mediastinum. These distribution characteristics of primary lesions were consistent with previous study (). More interestingly, all our cystic neuroblastoma cases were adrenal in origin. Some researches (, ) posit that the development of perinatal neuroblastoma and its cystic variant may be associated with nodular aggregations of neuroblasts during adrenal gland ontogeny. Accurate pathological identification is essential for the diagnosis and subtyping of congenital neuroblastoma. According to the 5th Edition of the WHO Classification of Pediatric Tumors (), a combined immunohistochemical panel covering neuronal and neural crest biomarkers, including phox2B, Syn, NF and CgA, is recommended to assist pathological diagnosis. All of our 15 cases expressed diffuse and strong signals of Phox2B in immunohistochemical examination, as its highest diagnostic specificity among the above markers, it maintains stable immunoreactivity even in undifferentiated neuroblastoma subtypes (, ). Syn and CgA were diffusely positive in 13 cases with other 2 cases showed focal positivity. NF were variably expressed. Moreover, S100 protein can specifically label Schwannian stromal components, which facilitates the differentiation of neuroblastoma from other neuroblastic neoplasms with similar morphological features, and acts as a supplementary indicator for pathological differential diagnosis (). Overall, the immunohistochemical expression patterns of these biomarkersaligned with the diagnostic criteria established by the WHO and previous studies (). Amplification of the MYCN oncogene is closely linked to the aggressive biological behavior of tumors and represents the most significant independent prognostic risk factor within the neuroblastoma risk stratification framework (, ). The Neuroblastoma Expert Panel of the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology advocates for the assessment of MYCN amplification status in all neuroblastoma cases, including the neuroblastoma nodule components found in nodular ganglioneuroblastoma (). Among segmental chromosomal aberrations in neuroblastoma, deletion of genetic material on the long arm of chromosome 11 (11q), is the most extensively characterized and serves as an independent prognostic indicator of poor outcome (, ). In patients aged over 18 months, the presence of segmental chromosomal aberrations, particularly 11q deletion, correlates with reduced event-free survival and overall survival rates (). The Biology Committee of the International Neuroblastoma Risk Group (INRG) recommends that FISH testing for the MYCN and KMT2A genes be performed in neuroblastoma (). In the current investigation, none of the 11 cases of congenital neuroblastoma demonstrated amplification of the MYCN gene, and analysis of the KMT2A (11q23) gene in four cases yielded negative results. These observations suggest potential molecular differences between this subtype and conventional neuroblastoma. Nevertheless, the relatively small sample size of 15 cases constitutes a limitation that may impact the generalizability of the findings. In the case presented herein (Case 15), the primary tumor demonstrated progressive enlargement over a 22-month follow-up period, culminating in complete surgical excision. Histopathological analysis revealed a heterogeneous composition comprising poorly differentiated neuroblastoma (with some anaplastic cells), differentiating neuroblastoma, mixed-type ganglioneuroblastoma, and mature intermediate-type ganglioneuroma, accompanied by synchronous cervical lymph node metastasis. Partial separate tumor nodules exhibited a marked deficiency in Schwannian stroma, consistent with those reported in the existing literature (, ). This tumor entity encompasses a distinct subtype known as composite neuroblastoma, classified under nodular neuroblastoma (Neuroblastoma, nodular, NBn). Its defining features include the presence of multiple well-demarcated nodular lesions within the tumor, each representing components at varying stages of neuroblast differentiation (e.g., poorly differentiated, differentiating). Unlike conventional nodular neuroblastoma, the overall tumor background is notably deficient in Schwannian stroma, and the tumor cells within discrete nodules derive from clonally distinct populations exhibiting marked biological heterogeneity. Some scholars (, ) advocated for the inclusion of composite neuroblastoma in forthcoming revisions of the International Neuroblastoma Pathology Classification (INPC). According to extant literature (, ), this multi-component histological pattern aligns with the “age-related maturation sequence” characteristic of NBn, wherein distinct clonal components correspond to various stages of differentiation and maturation during tumor progression. The cervical lymph node metastasis observed in Case 15 indicates biologically aggressive intratumoral clones. This observation is congruent with the clinical and pathological paradigm of NBn, wherein prognosis is predominantly influenced by invasive clones. Although Case 15 lacked MYCN amplification and KMT2A (11q23) abnormalities and exhibited a low MKI, the presence of anaplastic nodules may account for the tumor’s aggressive biological behavior. This study demonstrates that serum NSE serves as a relatively reliable preoperative diagnostic biomarker for congenital neuroblastoma, whereas the diagnostic utility of VMA is comparatively limited. Nonetheless, the efficacy of NSE as a sole indicator for early detection of postoperative recurrence is constrained. Transient postoperative elevations or dynamic fluctuations in NSE levels may represent nonspecific pathophysiological responses to tumor resection rather than definitive markers of recurrence. Furthermore, normal NSE concentrations do not preclude the possibility of recurrence, as evidenced by cases in this study where NSE levels remained within normal ranges despite tumor relapse. Consequently, clinical diagnosis and management should clearly differentiate the diagnostic roles of these two biomarkers. Postoperative surveillance should move beyond reliance on a single biomarker and instead implement a comprehensive monitoring strategy that integrates regular serum NSE assessments with imaging modalities such as radiological imaging examinations. This multifaceted approach can mitigate the limitations inherent to NSE measurement, facilitate earlier detection of recurrence risk, and ultimately enhance long-term outcomes in pediatric patients. Importantly, dynamic alterations in serum NSE levels and imaging findings exhibit a strong correlation with disease status, serving as reliable indicators for monitoring postoperative recovery and early recurrence risk. Consequently, these parameters represent essential components of clinical follow-up protocols for congenital neuroblastoma. Overall, the prognosis for congenital neuroblastoma appears favorable; most affected patients do not require adjuvant radiotherapy or chemotherapy following surgical resection but instead undergo long-term standardized clinical surveillance (). This single-center retrospective study enrolled 15 children diagnosed with congenital neuroblastoma, and postoperative tumor recurrence was observed in only one case, with a limited sample size. Our results indicate that serum NSE alone cannot reliably predict tumor recurrence, whereas the combination of NSE and imaging examinations is promising for postoperative prognostic evaluation and recurrence surveillance in these pediatric patients. Further large-sample, multicenter clinical studies are required to validate this conclusion and establish standardized postoperative follow-up protocols. Funding Statement The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the Wuhan Municipal Health Commission (WZ22Q06). Footnotes Ethics statement The studies involving humans were approved by Medical Ethics Committee of Wuhan Children’s Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants’ legal guardians/next of kin. Generative AI statement The author(s) declared that Generative AI was not used in the creation of this manuscript. Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us. Publisher’s note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.